<DOC>
	<DOCNO>NCT02254382</DOCNO>
	<brief_summary>This multicenter , prospective , randomized clinical trial ( pilot study ) . 20 participant diastolic heart failure assign ventilation therapy ( AutoSet CS ™ ASV device ; therapy group ) . The trial run 6 month , change echocardiographic parameter diastolic leave ventricular function , sleep quality life parameter evaluate .</brief_summary>
	<brief_title>Positive Airway Pressure Therapy Study Sleep Apnea Diastolic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Heart Failure , Diastolic</mesh_term>
	<criteria>Clinical sign symptom heart failure accord ESC guideline Echocardiographic evidence preserve systolic leave ventricular function ( echocardiographic leave ventricular ejection fraction &gt; 50 % ) Polysomnographic evidence least moderate sleepdisordered breathing : apneahypopnea index ( AHI ) &gt; 15 / h ≥ 50 % central event central AHI ≥ 10/h ( AHI base total sleeping time , TST ) BNP NTpro BNP ≥ 300 pg / ml NYHA class II III Patient tolerate ventilation treatment ( 1h sample ventilation ) Stable drug therapy last 4 week prior randomization ( iv diuretic therapy increase dose diuretic ≥ 100 % ) Minimum age patient 18 year patient willing undergo study procedure sign informed consent Oxygen saturation ( sO2 ) &lt; 92 % day peace without O2 therapy , measure baseline ( start time ) pulse oximetry polysomnography cape . BGA ( measurement must max . Lie back 1 week ) Patients , risk professional symptomatic sleep apnea Known COPD FEV1 &lt; 70 % patient NYHA stadium IV Advanced congenital heart defect pericardial disease Existing PAP bilevel therapy ( include adaptive servoventilation ) last 3 month Acute cardiac event last 3 month BMI ≥ 35kg / m² Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>diastolic heart failure</keyword>
</DOC>